Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Non-Current Deffered Revenue (2018 - 2019)

Champions Oncology has reported Non-Current Deffered Revenue over the past 2 years, most recently at $851000.0 for Q2 2019.

  • Quarterly results put Non-Current Deffered Revenue at $851000.0 for Q2 2019, up 87.44% from a year ago — trailing twelve months through Apr 2019 was $851000.0 (up 87.44% YoY), and the annual figure for FY2019 was $851000.0, up 87.44%.
  • Non-Current Deffered Revenue for Q2 2019 was $851000.0 at Champions Oncology, up from $733000.0 in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for CSBR hit a ceiling of $851000.0 in Q2 2019 and a floor of $454000.0 in Q2 2018.